Literature DB >> 23917475

Comparison study of two commercially available methods for the determination of infliximab, adalimumab, etanercept and anti-drug antibody levels.

Begoña Ruiz-Argüello, Ainhoa Ruiz del Agua, Nerea Torres, Alberto Monasterio, Antonio Martínez, Daniel Nagore.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23917475     DOI: 10.1515/cclm-2013-0461

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


× No keyword cloud information.
  15 in total

1.  Comparison of two ELISA versions for infliximab serum levels in patients diagnosed with ankylosing spondylitis.

Authors:  Diana Hernández-Flórez; Lara Valor; Inmaculada de la Torre; Juan Carlos Nieto; Lina Martínez-Estupiñán; Carlos González; Francisco Javier López-Longo; Indalecio Monteagudo; Jesús Garrido; Esperanza Naredo; Luis Carreño
Journal:  Rheumatol Int       Date:  2014-11-20       Impact factor: 2.631

2.  Clinical relevance of monitoring serum adalimumab levels in axial spondyloarthritis.

Authors:  José Miguel Senabre Gallego; Jose Rosas; Mariana Marco-Mingot; José Alberto García-Gómez; Gregorio Santos-Soler; Esteban Salas-Heredia; Ana Pons-Bas; Xavier Barber-Vallés; José Antonio Bernal-Vidal; Catalina Cano-Pérez; Mario García-Carrasco; Emilio Flores-Pardo
Journal:  Rheumatol Int       Date:  2019-03-21       Impact factor: 2.631

3.  Assays for measurement of TNF antagonists in practice.

Authors:  Niels Vande Casteele
Journal:  Frontline Gastroenterol       Date:  2016-03-08

4.  Practical application of acid dissociation in monitoring patients treated with adalimumab.

Authors:  Francisca Llinares-Tello; José Rosas-Gómez de Salazar; José Miguel Senabre-Gallego; Gregorio Santos-Soler; Carlos Santos-Ramírez; Esteban Salas-Heredia; Xavier Barber-Vallés; Juan Molina-García
Journal:  Rheumatol Int       Date:  2014-05-10       Impact factor: 2.631

5.  Drug levels, immunogenicity and assessment of active sacroiliitis in patients with axial spondyloarthritis under biologic tapering strategy.

Authors:  Miriam Almirall; Ramón Gimeno; Tarek Carlos Salman-Monte; Silvia Iniesta; Maria Pilar Lisbona; Joan Maymó
Journal:  Rheumatol Int       Date:  2016-01-27       Impact factor: 2.631

6.  Monitoring drug and antidrug levels: a rational approach in rheumatoid arthritis patients treated with biologic agents who experience inadequate response while being on a stable biologic treatment.

Authors:  Diana Mazilu; Daniela Opriş; Cecilia Gainaru; Mihaela Iliuta; Natalia Apetrei; Giorgiana Luca; Andreea Borangiu; Tania Gudu; Alexandra Peltea; Laura Groseanu; Cosmin Constantinescu; Ioana Saulescu; Violeta Bojinca; Andra Balanescu; Denisa Predeteanu; Ruxandra Ionescu
Journal:  Biomed Res Int       Date:  2014-05-20       Impact factor: 3.411

7.  Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.

Authors:  José Inciarte-Mundo; Julio Ramirez; Maria Victoria Hernández; Virginia Ruiz-Esquide; Andrea Cuervo; Sonia Raquel Cabrera-Villalba; Mariona Pascal; Jordi Yagüe; Juan D Cañete; Raimon Sanmarti
Journal:  Arthritis Res Ther       Date:  2016-07-08       Impact factor: 5.156

8.  Rapid Test for Infliximab Drug Concentration Allows Immediate Dose Adaptation.

Authors:  Thomas Van Stappen; Lize Bollen; Niels Vande Casteele; Konstantinos Papamichael; Gert Van Assche; Marc Ferrante; Séverine Vermeire; Ann Gils
Journal:  Clin Transl Gastroenterol       Date:  2016-12-08       Impact factor: 4.488

9.  Clinical performance of an infliximab rapid quantification assay.

Authors:  Fernando Magro; Joana Afonso; Susana Lopes; Rosa Coelho; Raquel Gonçalves; Paulo Caldeira; Paula Lago; Helena Tavares de Sousa; Jaime Ramos; Ana Rita Gonçalves; Paula Ministro; Isadora Rosa; Tânia Meira; Patrícia Andrade; João-Bruno Soares; Diana Carvalho; Paula Sousa; Ana Isabel Vieira; Joanne Lopes; Cláudia Camila Dias; Karel Geboes; Fátima Carneiro
Journal:  Therap Adv Gastroenterol       Date:  2017-08-11       Impact factor: 4.409

10.  Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays.

Authors:  Joana Afonso; Helena Tavares de Sousa; Isadora Rosa; João Carvalho; Cláudia Camila Dias; Fernando Magro
Journal:  Therap Adv Gastroenterol       Date:  2017-08-11       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.